Vaccination Against Cancer and Chronic Diseases
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of the Section “Vaccination Against Cancer and Chronic Diseases” is to highlight recent advances in vaccine-based approaches for the prevention and treatment of cancer and other chronic diseases. This Section will provide a platform for novel insights into immunological mechanisms, translational applications, and the development of next-generation therapeutic vaccines.
Scope
We welcome articles examining the design, development, and evaluation of vaccines targeting cancer and chronic diseases, including autoimmune disorders, metabolic syndromes, and chronic infections. Topics may include nanoparticle and virus-like particle-based technologies, mRNA and conventional vaccines, neoantigen discovery, tumor microenvironment-targeted immunotherapies, and personalized cancer vaccines. We invite submissions addressing preclinical and clinical studies, and encourage translational research that bridges experimental findings with human applications. We will consider original research articles, brief reports, reviews, and others relevant article types.
Keywords
- cancer vaccines
- chronic disease immunotherapy
- neoantigen discovery
- mRNA vaccines
- dendritic cell-based vaccines
- tumor immunology
- personalized immunotherapy
- preclinical models
- immune checkpoint inhibitors
- cancer prevention
- clinical trials
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Vaccines Targeting the Tumor Microenvironment: Challenges and Future Prospects (Deadline: 31 August 2025)
- Modulating CD4+ T Cells for Cancer Immunotherapy: Emerging Strategies and Applications (Deadline: 1 September 2025)
- Innovations in Immunotherapy: Advancements in Cancer Vaccines and Immune Modulation (Deadline: 30 September 2025)
- Personalised Cancer Vaccines (Deadline: 31 October 2025)
- Innovative Vaccines That Modulate the Immune System to Enhance Cancer Therapy (Deadline: 31 October 2025)
- Vaccines Targeting Dendritic Cells (Deadline: 31 October 2025)
- Cancer Vaccines and Immunotherapy: Latest Advances, Limitations and Prospects (Deadline: 30 November 2025)
- Cutting-Edge Cancer Vaccines Enhanced by Nanotechnology (Deadline: 31 December 2025)
- Vaccination or Infection and the Role of T Cells—the Response to Cancer, Autoimmunity or Inflammatory Diseases (Deadline: 31 December 2025)
- Development of Novel Mucosal Vaccines: Advances in Technology and Delivery (Deadline: 31 January 2026)
- Novel Immunotherapies, Cell Therapies and Cancer Vaccines (Deadline: 31 January 2026)
- Next-Generation Vaccine and Immunotherapy (Deadline: 31 January 2026)
- The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy (Deadline: 31 January 2026)
- Cancer Vaccines: Current Advances, Clinical Applications, and Future Directions (Deadline: 28 February 2026)
- Advances in Cancer Immunotherapy and Vaccines Research: 2nd Edition (Deadline: 20 March 2026)
- Cancer Vaccines: 4th Edition (Deadline: 31 March 2026)
- Cancer Vaccines and Immunotherapies (Deadline: 31 March 2026)
- Developing Recombinant Vaccines and Immunotherapy Strategies for Emerging Viral Diseases (Deadline: 31 March 2026)
- Epidemiology, Immunology, and Therapeutic Vaccines of Enteric Pathogens (Deadline: 31 March 2026)
- Oral Vaccines: Challenges, Immunity and Therapeutic Advances (Deadline: 30 April 2026)
- Tumor Vaccines: Current Processes, Prevailing Challenges and Future Perspectives (Deadline: 1 May 2026)
- Vaccines Based on Dendritic Cells: Breaking Barriers to New Immune Response Approach (Deadline: 31 May 2026)
- Therapeutic Cancer Vaccines: Advances, Challenges, and Future Directions (Deadline: 31 May 2026)
- Advances in ImmunoTherapy of Cancer (Deadline: 31 May 2026)
- Immune Imprinting: Effects, Mechanisms, and Implications for Vaccine Design (Deadline: 30 June 2026)
- Vaccination for Patients with Hematologic Diseases (Deadline: 31 August 2026)
Topical Collection
Following topical collection within this section is currently open for submissions: